GW Pharmaceuticals, which makes drugs derived from the cannabis plant, is scaling up its manufacturing capacity ahead of an expected approval of a new treatment for children with life-threatening epilepsy.

Christmas came early for cannabis research scientists. The U.S. Drug Enforcement Agency (DEA) decided to ease some of the regulatory requirements that had been imposed on those who were conducting FDA-approved clinical trials on cannabidiol (CBD).

Insys Therapeutics Inc. announced Tuesday, July 5, that the United States Food and Drug Administration (FDA) has approved the company’s drug Syndros, an orally administered liquid formulation of the synthetic cannabinoid dronabinol, according to a release.